Evidence map›Paper›PMID 39394467›Full record

ArticleEMBO reports2024

m

Anika Pupak, Irene Rodríguez-Navarro, Kirupa Sathasivam, Ankita Singh, Amelie Essmann, Daniel Del Toro, Silvia Ginés, Ricardo Mouro Pinto, Gillian P Bates, Ulf Andersson Vang Ørom and 2 more

Erratum issuedAbstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Review
  4. The mCells · 2025
    Review
  5. Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Anika PupakDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-2653-9189
Irene Rodríguez-NavarroDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.
Kirupa SathasivamDepartment of Neurodegenerative Disease, Huntington's Disease Centre and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL, London, WC1N 3BG, UK.
Ankita SinghDepartment for Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.ORCID 0000-0001-8339-3337
Amelie EssmannDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.
Daniel Del ToroDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.
Silvia GinésDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-9479-8185
Ricardo Mouro PintoCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-6744-2805
Gillian P BatesDepartment of Neurodegenerative Disease, Huntington's Disease Centre and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL, London, WC1N 3BG, UK.
Ulf Andersson Vang ØromDepartment for Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark.ORCID 0000-0002-0643-0592
Eulàlia MartíDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain.
Verónica BritoDepartament de Biomedicina, Facultat de Medicina, Institut de Neurosciències, Universitat de Barcelona, Barcelona, Spain. veronica.brito@ub.edu.ORCID 0000-0002-4137-0708

Funding

Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat DisordersR01NS126420 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Ricardo Mouro Pinto · 2022 to 2026
$2.0M
Generalitat de Catalunya (Government of Catalonia) 2018FI_B00487Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2020-113953RB-I00Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2020-116474RB-100Ministerio de Ciencia, Innovación y Universidades (MCIU) RE2021-097199Ministerio de Ciencia, Innovación y Universidades (MCIU) RTI2018-094374-B100NINDS NIH HHS R01 NS126420
6 · The paper itself

Abstract

In Huntington's disease (HD), aberrant processing of huntingtin (HTT) mRNA produces HTT1a transcripts that encode the pathogenic HTT exon 1 protein. The mechanisms behind HTT1a production are not fully understood. Considering the role of m

Indexed as

Huntingtin ProteinHuntington DiseaseIntronsMethyltransferasesRNA, MessengerAdenosineAnimalsHumansMethylationMiceMutationRNA Processing, Post-TranscriptionalRNA SplicingAdenosineHTT protein, humanHuntingtin ProteinMethyltransferasesMETTL3 protein, humanMettl3 protein, mouseN-methyladenosineRNA, MessengerHTT1aHuntington’s Diseasem6ARNA EditingSplicing

Identifiers

PMID39394467
PMCPMC11549361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.